Related Experiment Videos
A novel Helicobacter pylori cell-surface polysaccharide
Stacey Britton1, Erzsebet Papp-Szabo, Joanna Simala-Grant
1Department of Chemistry, University of Guelph, Guelph, ON N1G 2W1, Canada.
Carbohydrate Research
|June 1, 2005
Summary
Helicobacter pylori serotype O2 expresses a unique lipopolysaccharide (LPS) structure. This novel polysaccharide composition is crucial for developing a multivalent H. pylori vaccine.
Area of Science:
- Microbiology
- Immunology
- Carbohydrate Chemistry
Background:
- Helicobacter pylori infects over half the global population, causing various gastric diseases.
- Currently, no vaccine exists for H. pylori, a known human carcinogen, with treatment relying on antibiotics.
- Previous studies identified six H. pylori serotypes based on lipopolysaccharide (LPS) antigenic variations.
Purpose of the Study:
- To investigate the structural variability of H. pylori cell-surface glycans for multivalent vaccine development.
- To characterize the novel LPS structure of H. pylori serotype O2.
Main Methods:
- Analysis of lipopolysaccharide (LPS) structures from different H. pylori serotypes.
- Detailed structural elucidation of the polysaccharide component of H. pylori serotype O2 LPS.
Main Results:
- H. pylori serotypes O1, O3, O4, and O6 possess LPS with 'Lewis O-chains' or heptoglycan domains.
- H. pylori serotype O2 produces a distinct LPS with an elongated polysaccharide composed of alternating 2- and 3-monosubstituted alpha-D-Glcp residues.
- This unique structure explains the serospecificity of H. pylori serotype O2.
Conclusions:
- The novel LPS structure of H. pylori serotype O2 differs significantly from previously described serotypes.
- This unique bacterial polysaccharide is essential for inclusion in a multivalent H. pylori LPS-based vaccine formulation.